Combining options in metastatic prostate cancer

被引：1
|
作者：
Kopp, Ryan P. [1 ,2 ,3 ]
Beer, Tomasz M. [3 ]
机构：
[1] Oregon Hlth & Sci Univ, Dept Urol, Portland, OR 97201 USA
[2] Portland VA Med Ctr, Urol Sect, Portland, OR USA
[3] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
来源：
NATURE REVIEWS UROLOGY | 2019年 / 16卷 / 10期
关键词：
D O I：
10.1038/s41585-019-0217-z
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.
引用
收藏
页码：569 / 570
页数：2
相关论文
共 50 条
  • [1] Combining options in metastatic prostate cancer
    Ryan P. Kopp
    Tomasz M. Beer
    [J]. Nature Reviews Urology, 2019, 16 : 569 - 570
  • [2] Metastatic Prostate Cancer: Treatment Options
    Achard, Verane
    Putora, Paul Martin
    Omlin, Aurelius
    Zilli, Thomas
    Fischer, Stefanie
    [J]. ONCOLOGY, 2021, : 48 - 59
  • [3] Expanding Treatment Options for Metastatic Prostate Cancer
    Antonarakis, Emmanuel S.
    Eisenberger, Mario A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21): : 2055 - 2058
  • [4] New treatment options for patients with metastatic prostate cancer
    Snoeks, L. L.
    Ogilvie, A. C.
    van Haarst, E. P.
    Siegert, C. E. H.
    [J]. NETHERLANDS JOURNAL OF MEDICINE, 2013, 71 (06): : 290 - 294
  • [5] Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer
    Steven B. Zeliadt
    David F. Penson
    [J]. PharmacoEconomics, 2007, 25 : 309 - 327
  • [6] Pharmacoeconomics of available treatment options for metastatic prostate cancer
    Zeliadt, Steven B.
    Penson, David F.
    [J]. PHARMACOECONOMICS, 2007, 25 (04) : 309 - 327
  • [7] Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options
    Gartrell, Benjamin A.
    Coleman, Robert
    Efstathiou, Eleni
    Fizazi, Karim
    Logothetis, Christopher J.
    Smith, Matthew R.
    Sonpavde, Guru
    Sartor, Oliver
    Saad, Fred
    [J]. EUROPEAN UROLOGY, 2015, 68 (05) : 850 - 858
  • [8] The evolving options in metastatic castration-sensitive prostate cancer
    Hamilou, Zineb
    [J]. CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2020, 14 (03) : 270 - 275
  • [9] Inhibition of Angiogenesis: Treatment Options for Patients with Metastatic Prostate Cancer
    William D. Figg
    Erwin A. Kruger
    Douglas K. Price
    Sonia Kim
    William D. Dahut
    [J]. Investigational New Drugs, 2002, 20 : 183 - 194
  • [10] Treatment options for metastatic hormone-sensitive prostate cancer
    Kostos, Louise
    Murphy, Declan G.
    [J]. LANCET ONCOLOGY, 2022, 23 (10): : 1234 - 1235
12345